SEC Form 4 · accession 0000899243-15-006392
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Oct 5, 2015
Accepted (ET)
Oct 6, 2015 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Oct 5, 2015 | X | 399,659 | $3.54 | A | 1,380,874 | I | WFD Ventures Fund II |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF1,F2 | $3.54 | Oct 5, 2015 | X | 399,659 | D | — | Oct 11, 2015 | Ordinary Shares | 399,659 | 0 | I |
Explanation of responses
- F1Mr. Doyle is a managing director of WFD Ventures LLC, the sole member of WFD-GP II, LLC, which is the general partner of WFD Ventures Fund II. Mr. Doyle possesses sole voting and investment power over shares owned by WFD Ventures Fund II (subject to certain rights of the advisory board of WFD Ventures Fund II to approve sales of any of the shares owned by WFD Ventures Fund II).
- F2Currently exercisable as of the date hereof.
Remarks
This Form 4 is filed for William F. Doyle and WFD Ventures Fund II.